首页 | 本学科首页   官方微博 | 高级检索  
检索        

注射用牛肺表面活性剂联合氨溴索治疗早产儿呼吸窘迫综合征180例疗效观察
引用本文:李艳红.注射用牛肺表面活性剂联合氨溴索治疗早产儿呼吸窘迫综合征180例疗效观察[J].中国基层医药,2014(10):1493-1495.
作者姓名:李艳红
作者单位:周口市中心医院新生儿重症监护室,河南省周口466000
摘    要:目的:观察牛肺表面活性剂(珂立苏)联合氨溴索对早产儿呼吸窘迫综合征( NRDS)的治疗效果。方法将180例 NRDS患儿根据数字表法随机分为观察组和对照组,每组90例。两组均给予常规治疗,另外对照组给予氨溴索治疗,观察组在对照组治疗基础上加用珂立苏。比较两组疗效。结果与对照组治疗后比较,观察组患儿PaO2及pH值均升高,PaCO2值下降,其中两组PaO2及PaCO2值比较差异均有统计学意义(t=5.91、13.16、29.89、2.98、5.11、8.13,均P<0.05);观察组机械通气时间、住院天数分别为(45.30±5.35)h、(10.01±2.24)d,均明显优于对照组的(68.27±6.13)h、(17.24±2.39)d(t=26.78、20.94,均P<0.05)。结论珂立苏联合氨溴索能明显改善NRDS患儿的缺氧症状,降低机械通气时间、住院天数,改善患儿预后。

关 键 词:呼吸窘迫综合征  新生儿  肺表面活性物质相关蛋白质类  氨溴索

Observation of the effect of pulmonary surfactant-associated proteins combined with ambroxol in the treat-ment of 180 children with congenital alveolar dysplasia neonatal respiratory distress syndrome
Li Yanhong.Observation of the effect of pulmonary surfactant-associated proteins combined with ambroxol in the treat-ment of 180 children with congenital alveolar dysplasia neonatal respiratory distress syndrome[J].Chinese Journal of Primary Medicine and Pharmacy,2014(10):1493-1495.
Authors:Li Yanhong
Institution:Li Yanhong (Department of NICU, the Central Hospital of Zhoukou, Zhoukou, Henan 466000, China)
Abstract:Objective To observe the effect of pulmonary surfactant-associated proteins ( Kelisu) combined with ambroxol in the treatment of 180 congenital alveolar dysplasia children with neonatal respiratory distress syndrome ( NRDS) .Methods According to random number table ,180 congenital alveolar dysplasia children with NRDS were randomly divided into the observation group and control group , 90 cases in each group .In addition to conventional therapy,the control group was given ambroxol hydrochloride treatment ,the observation group was given Kelisu on thebasis of treatment of the control group.The treatment effect was compared between the two groups .Results Comparedwith the control group,after treatment the values of PaO2 and pH were significantly increased,PaCO2 significantly decreasedin the observation group(t =5.91,13.16,29.89,2.98,5.11,8.13,all P 〈0.05).The duration of mechanicalventilation,length of hospital stay were (45.30 ±5.35)h,(10.01 ±2.24)d in the observation group,respectively,which were significantly better than(68.27 ±6.13)h,(17.24 ±2.39)d]in the control group(t =26.78,20.94,all P 〈0.05).Conclusion Kelisu combined with hydrochloride ambroxol can significantly improve hypoxia symp -toms in NRDS children,reduce the duration of mechanical ventilation and length of hospital stay ,improve the prognosis.
Keywords:Respiratory distress syndrome  newborn  Pulmonary surfactant-associated proteins  Ambroxol
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号